Peacock E E
Am Surg. 1978 Nov;44(11):693-8.
Pharmacological control of unwanted scar tissue theoretically is possible in human beings and has been proven to be practical and effective treatment in laboratory animals. The most advanced research involves prevention of the development of helical structure and transport of collagen by administration of proline analogues and controlled induction of lathyrism by administration of Beta-aminopropionitrile. The toxicity of proline analogues has prevented human testing; BAPN presently is being tested or has been tested in patients with scleroderma, flexor tendon adhesions, posterior urethral strictures, and surface keloids. At this time, highly purified BAPN appears generally non-toxic and is capable of exerting a higly selective and significant lathyrogenic effect on the healing wound. The combination of BAPN and other drugs, such as Colchicine, which increases collagenolytic activity, probably will make safe control of clinical properties of scar tissue possible within the next 24 months.
理论上,对人体多余瘢痕组织进行药物控制是可行的,并且已在实验动物身上被证明是切实有效的治疗方法。最先进的研究包括通过给予脯氨酸类似物来预防螺旋结构的形成和胶原蛋白的转运,以及通过给予β-氨基丙腈来控制性地诱发骨生成异常。脯氨酸类似物的毒性阻碍了人体试验;目前,β-氨基丙腈正在或已经在硬皮病、屈肌腱粘连、后尿道狭窄和体表瘢痕疙瘩患者身上进行试验。此时,高度纯化的β-氨基丙腈通常似乎无毒,并且能够对愈合伤口产生高度选择性和显著的致骨生成异常作用。β-氨基丙腈与其他药物(如秋水仙碱,可增加胶原酶活性)的联合使用,可能会在未来24个月内实现对瘢痕组织临床特性的安全控制。